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Nasal drug delivery has become one of the most researched alternative drug administration 
route in the last decades. The reason of the increasing interest is, that due to the unique 
anatomical and physiological properties, local, systemic and direct Central Nerve System (CNS) 
effects are available via nasal administration. In the case of therapies (e.g. CNS diseases, brain 
tumors), where the point of attack is in the brain, nasal drug administration can improve the 
efficiency of the treatment. Powders have some favourable physicochemical properties over 
liquid formulations, so in some cases they are preferred dosage forms [1]. Reducing the 
particle size to the nano range is also a common way to modify the properties of a drug and 
can affect its bioavailability in a positive way [2]. The aim of this research is to formulate and 
develop one or more alternative dosage forms for lamotrigine (LAM), that is a BCS II. 
antiepileptic drug and only available on the market in tablet form [3]. Since the beginning a 
nanosized LAM containing nasal powder has been produced, the process of sample 
preparation has been optimized and the samples were tested in vivo [4].  
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